Literature DB >> 10824750

The incidence of splenectomy is decreasing: lessons learned from trauma experience.

A T Rose1, M I Newman, J Debelak, C W Pinson, J A Morris, D D Harley, W C Chapman.   

Abstract

Over the past decade, splenic preservation has become a well-reported and accepted principle in trauma management. The reasons for splenic preservation may have influenced nontraumatic surgical management as well. To investigate the changing incidence and indications for splenectomy, we conducted a 10-year review of all splenectomies at our institution. During this time, between January 1, 1986, and December 31, 1995, 896 patients underwent splenectomy. Hospital charts and records were examined to determine the etiology and incidence of splenectomy. Indications were classified as: 1) trauma, i.e., performed for blunt or penetrating injury; 2) hematologic malignancy, i.e., therapy or staging of underlying leukemia, Hodgkin's lymphoma, or non-Hodgkin's lymphoma; 3) cytopenia, i.e., treatment of thrombocytopenia, anemia, or leukopenia; 4) iatrogenic, i.e., injury during another procedure; 5) incidental, i.e., required for adjacent organ resection; 6) portal hypertension, i.e., left-sided portal hypertension or during shunting procedure; 7) diagnostic, i.e., uncertainty excluding hematologic malignancy; or 8) other, i.e., miscellaneous indications. Trauma accounted for 41.5 per cent of all splenectomies during this time period, hematologic malignancy 15.4 per cent, cytopenia 15.6 per cent, incidental 12.3 per cent, iatrogenic 8.1 per cent, portal hypertension 2.3 per cent, diagnostic 2.0 per cent, and other 2.7 per cent. Comparing the first and second 5-year time periods, the following increases/decreases in average annual incidence were noted: splenectomy for all indications, -36.9 per cent; trauma, -32.9 per cent; hematologic malignancy, -51.4 per cent; cytopenia, 35.1 per cent; incidental, -35.9 per cent; iatrogenic, -30.2 per cent; diagnostic, +4.9 per cent, and other, -57 per cent. Traumatic injury to the spleen remains the most common indication for splenectomy, but the incidence has decreased dramatically over the past 10 years. Splenectomies for treatment of hematologic malignancies and cytopenia, as well as incidental and iatrogenic splenectomies, have also decreased significantly. Only the incidence of diagnostic splenectomy has remained stable. Although initiated within the field of trauma, the advantages of splenic preservation now appear to be well recognized beyond that field.

Entities:  

Mesh:

Year:  2000        PMID: 10824750

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  7 in total

1.  The basis for splenic segmental dearterialization: a post-mortem study.

Authors:  D Ignjatovic; B Stimec; V Zivanovic
Journal:  Surg Radiol Anat       Date:  2004-10-29       Impact factor: 1.246

Review 2.  Vascular complications after splenectomy for hematologic disorders.

Authors:  Shelley E Crary; George R Buchanan
Journal:  Blood       Date:  2009-07-27       Impact factor: 22.113

3.  Splenectomy increases the subsequent risk of systemic lupus erythematosus.

Authors:  Chao-Yu Hsu; Hsuan-Ju Chen; Chung Y Hsu; Chia-Hung Kao
Journal:  Rheumatol Int       Date:  2015-11-02       Impact factor: 2.631

Review 4.  Laparoscopic splenectomy for lymphoproliferative disease.

Authors:  R M Walsh; F Brody; N Brown
Journal:  Surg Endosc       Date:  2003-12-29       Impact factor: 4.584

5.  Laparoscopic splenectomy for treatment of splenic marginal zone lymphoma.

Authors:  Zhong Wu; Jin Zhou; Xin Wang; Yong-Bin Li; Ting Niu; Bing Peng
Journal:  World J Gastroenterol       Date:  2013-06-28       Impact factor: 5.742

6.  Pattern of splenectomy indications in kashan shahid-beheshti hospital: a 5-year study.

Authors:  Tahere Khamechian; Javad Alizargar; Maryam Farzanegan
Journal:  Arch Trauma Res       Date:  2013-02-01

7.  Increased Risk of Hemorrhagic and Ischemic Strokes in Patients With Splenic Injury and Splenectomy: A Nationwide Cohort Study.

Authors:  Jiun-Nong Lin; Cheng-Li Lin; Ming-Chia Lin; Chung-Hsu Lai; Hsi-Hsun Lin; Chih-Hui Yang; Chia-Hung Kao
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.